Lupin receives Indian marketing approval for pegfilgrastim biosimilar

Lupin has received Indian marketing approval for a pegfilgrastim biosimilar used to reduce the risk of chemotherapy-induced neutropenia.

The approval expands Lupin's biosimilar portfolio in oncology supportive care and provides another locally manufactured treatment option for patients receiving myelosuppressive chemotherapy.

Pegfilgrastim is a long-acting granulocyte colony-stimulating factor used to reduce the incidence and duration of neutropenia and related infection risk following cancer treatment.

Field	Content
Alert Type	Approval
Drug Name	Pegfilgrastim biosimilar
Company	Lupin
Regulatory Authority	Indian regulatory authorities
Approval Type	Marketing approval
Indication	Reduction of chemotherapy-induced neutropenia in patients receiving myelosuppressive anticancer treatment
Therapy Area(s)	Oncology; supportive care
Technology or Modality	Biosimilar; granulocyte colony-stimulating factor
Geography	India
What Happened	Lupin received marketing approval in India for its pegfilgrastim biosimilar.
Why It Matters	The approval adds another biosimilar option in oncology supportive care and expands access to long-acting neutropenia prevention for patients receiving chemotherapy.
Supporting Context	Pegfilgrastim is a long-acting granulocyte colony-stimulating factor used to stimulate neutrophil production following myelosuppressive chemotherapy.
Key Takeaway	Lupin has added an approved pegfilgrastim biosimilar to its Indian oncology supportive-care portfolio.
What to Watch	Commercial launch, physician uptake and pricing relative to existing pegfilgrastim products in India.
Primary Source	ETPharma.com
Relevant Date	10 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com